Key result
Platelet glycoprotein IIb/IIIa antagonists have potential applications in the treatment of acute ischemic stroke and as adjunctive therapy to carotid angioplasty.
Why the study?
Do platelet glycoprotein IIb/IIIa antagonists improve safety and efficacy compared with standard rt-PA in patients with acute ischemic stroke?
Population
Patients with acute ischemic stroke
Comparison
Platelet glycoprotein IIb/IIIa antagonists… vs Standard recombinant tissue plasminogen activator
Design
Review
Authors
Loading...
May support exploratory roles in acute ischemic stroke; leaves open efficacy versus rt-PA pending randomized trials.
Do platelet glycoprotein IIb/IIIa antagonists improve safety and efficacy compared with standard rt-PA in patients with acute ischemic stroke?
Platelet glycoprotein IIb/IIIa antagonists may have potential applications in the treatment of acute ischemic stroke and as adjunctive therapy to carotid angioplasty.
Bogousslavsky et al. (2001) conducted a review in acute ischemic stroke. Platelet glycoprotein IIb/IIIa antagonists vs. standard recombinant tissue plasminogen activator (rt-PA) was evaluated. Platelet glycoprotein IIb/IIIa antagonists have potential applications in the treatment of acute ischemic stroke and as adjunctive therapy to carotid angioplasty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: